The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
Tuesday, June 04, 2024
Special Program
![Business Development and Finance](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Busines_MTC.png)
32AB
Chad Wessel, BIO’s Director of Industry Research, will provide an overview of recent investment and deal trends for emerging therapeutic companies, as well as an update on the R&D pipeline and recent FDA approvals. The BIO Industry Analysis team publishes quarterly interactive data on licensing, M&A, venture capital, IPOs, follow-on public offerings, and FDA approvals at www.bio.org/iareports.
Speakers